| Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
T | 0.750 | CausalMutation | CLINVAR | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | 22608338 | 2012 |
|||
|
T | 0.750 | CausalMutation | CLINVAR | Epidermal growth factor receptor blockers for the treatment of ovarian cancer. | 21975775 | 2011 |
|||
|
T | 0.750 | CausalMutation | CLINVAR | Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. | 21683865 | 2011 |
|||
|
T | 0.750 | CausalMutation | CLINVAR | Improved survival with vemurafenib in melanoma with BRAF V600E mutation. | 21639808 | 2011 |
|||
|
T | 0.750 | CausalMutation | CLINVAR | Inhibition of mutated, activated BRAF in metastatic melanoma. | 20818844 | 2010 |
|||
|
T | 0.750 | CausalMutation | CLINVAR | KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. | 19018267 | 2008 |
|||
|
T | 0.750 | CausalMutation | CLINVAR | Mutations of the BRAF gene in human cancer. | 12068308 | 2002 |
|||
|
T | 0.700 | GeneticVariation | CLINVAR | Prospective enterprise-level molecular genotyping of a cohort of cancer patients. | 25157968 | 2014 |
|||
|
C | 0.700 | CausalMutation | CLINVAR | BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. | 22798288 | 2012 |
|||
|
C | 0.700 | CausalMutation | CLINVAR | Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. | 21683865 | 2011 |
|||
|
C | 0.700 | CausalMutation | CLINVAR | Epidermal growth factor receptor blockers for the treatment of ovarian cancer. | 21975775 | 2011 |
|||
|
C | 0.700 | CausalMutation | CLINVAR | Mutations of the BRAF gene in human cancer. | 12068308 | 2002 |